Abstracts tagged "dermatomyositis"

Abstract Number: 1949 • ACR Convergence 2020
CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro
Spandana Maddukuri¹, Jay Patel², Christina Bax³, Maria Wysocka³ and Victoria Werth⁴, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia
Background/Purpose: Dermatomyositis (DM) patients report poor quality of life due to disease activity and persistent itch. Lenabasum is an oral non-immunosuppressive, non-psychoactive cannabinoid type 2…
Abstract Number: 044 • 2020 Pediatric Rheumatology Symposium
Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network
Sonia Savani¹, Natasha Ruth ², Paul Nietert ¹, Gabrielle Morgan ³, Mileka Gilbert ¹ and Lauren Pachman ⁴, ¹Medical University of South Carolina, Charleston, South Carolina, ²Medical University South Carolina, Charleston, South Carolina, ³Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois, ⁴Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, 303 E Superior, Chicago
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare systemic autoimmune disease characterized by vasculopathy and rash. The Bohan-Peter criteria for dermatomyositis are not ideal. There is…
Abstract Number: 1933 • 2019 ACR/ARP Annual Meeting
Tumorigenesis Related Gene Identification in Dermatomyositis Using Meta-Analysis
Jihad Aljabban¹, Saad Syed ², Sharjeel Syed ³, Kalyn Hoffman ⁴, Laith Hasan ⁵, Nikhil Adapa ¹, Zahir Allarakhia ⁶, Dexter Hadley ⁷, Mohamad Aljabban ⁸ and Wael Jarjour ⁹, ¹Ohio State University College of Medicine, Columbus, ²Stanford School of Medicine, Stanford, ³Stanford School of Medicine, Stanford, CA, ⁴The Ohio State University College of Medicine, Columbus, OH, ⁵Tulane School of Medicine, New Orleans, ⁶Ohio State University College of Medicine, Columbus, OH, ⁷Institute for Computational Health Sciences, San Francisco, ⁸Genesys Health Systems, Grand Blanc, MI, ⁹Ohio State College of Medicine, Columbus, OH
Background/Purpose: Dermatomyositis (DM) is a progressive, systemic autoimmune disease-causing inflammatory changes in the skin and skeletal muscles. DM is associated with carcinomas of the ovary,…
Abstract Number: 1934 • 2019 ACR/ARP Annual Meeting
Tripartite Motif (TRIM) Gene Family Expression in Dermatomyositis
Jihad Aljabban¹, Sharjeel Syed ², Saad Syed ³, Zarife Sahenk ⁴, Noah Weisleder ⁵, Kevin McElhanon ⁵, Kalyn Hoffman ⁶, Nikhil Adapa ¹, Zahir Allarakhia ⁷, Laith Hasan ⁸, Dexter Hadley ⁹, Mohamad Aljabban ¹⁰ and Wael Jarjour ¹¹, ¹Ohio State University College of Medicine, Columbus, ²Stanford School of Medicine, Stanford, CA, ³Stanford School of Medicine, Stanford, ⁴Department of Neurology, Research Institute at Nationwide Children’s Hospital, Columbus, OH, ⁵Dorothy M. Davis Heart and Lung Research Institute & Dept. of Physiology & Cell Biology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶The Ohio State University College of Medicine, Columbus, OH, ⁷Ohio State University College of Medicine, Columbus, OH, ⁸Tulane School of Medicine, New Orleans, ⁹Institute for Computational Health Sciences, San Francisco, ¹⁰Genesys Health Systems, Grand Blanc, MI, ¹¹Ohio State College of Medicine, Columbus, OH
Background/Purpose: Dermatomyositis (DM) is a progressive, systemic autoimmune disease causing inflammatory changes to the skin and skeletal muscles. TRIM family proteins are composed of approximately…
Abstract Number: 93 • 2019 ACR/ARP Annual Meeting
Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis
Amrutesh Puranik¹, Mark Jensen ², Regine Tipon ³, Yogita Ghodke-Puranik ³, Valeria Mezzano ⁴, Shanmugapriya Selvaraj ⁵, Theresa Wampler Muskardin ⁴, Cynthia Loomis ⁴, Ann Reed ⁶, Lauren Pachman ⁷ and Timothy Niewold ⁵, ¹NYU Langone Health, New York, NY, ²Colton Center for Autoimmunity, NYU School of Medicine, New York, NY, ³Colton Center for Autoimmunity, NYU School of Medicine, New York, ⁴New York University Langone Health, New York, ⁵New York University Langone Health, New York, NY, ⁶Duke University School of Medicine, Durham, NC, ⁷Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: T and B cells come together in ectopic lymphoid aggregates in myositis, suggesting that local T:B cell interactions could play a role in disease. …
Abstract Number: 2739 • 2019 ACR/ARP Annual Meeting
Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis
Mika Tabata¹, Kavita Sarin ², Karen Page ³, Christine Huard ³, Shanrong Zhao ³, Donald Bennett ³, Jillian Johnson ³, Kristen Johnson ³ and David Fiorentino ², ¹Stanford University School of Medicine, Stanford, CA, ²Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ³Pfizer, Boston
Background/Purpose: Interferon (IFN) signaling is upregulated in dermatomyositis (DM) and thought to play a role in pathogenesis. An IFN gene signature in peripheral blood of…
Abstract Number: 395 • 2019 ACR/ARP Annual Meeting
Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis
Soumyasri Kambhatla¹, Carrie Richardson ², Prasanth Lingamaneni ³ and Augustine Manadan ², ¹John H. Stroger Hospital of Cook County, Chicago, ²Rush University Medical Center, Chicago, IL, ³John H. Stroger Hospital of Cook County, Chicago, IL
Background/Purpose: A subset of patients with dermatomyositis may fail to achieve remission despite treatment. Nevertheless, the risk factors for failure to achieve remission in dermatomyositis are largely…
Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Yoo Jung Kim¹, Elena Schiopu ², Katalin Dankó ³, Tahseen Mozaffar ⁴, Srinivas Chunduru ⁵, Kirstin Lees ⁶, Namita Goyal ⁴, David Fiorentino ⁷ and Kavita Sarin ⁷, ¹Stanford University School of Medicine, Redwood City, CA, ²Department of Rheumatology, University of Michigan, Ann Arbor, ³Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary, ⁴Department of Neurology, University of California Irvine, Irvine, CA, ⁵Idera Pharmaceuticals, Inc., Cambridge, MA, ⁶Idera Pharmaceuticals, Inc., Cambridge, ⁷Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…
Abstract Number: 405 • 2019 ACR/ARP Annual Meeting
Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Mohammad Ryadh Pokeerbux¹, Luc Dauchet ², Benjamin Lopez ³, Hélène Maillard ¹, Sandrine Morell-Dubois ¹, Eric Auxenfants ⁴ and Eric Hachulla ⁵, ¹Department of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, Lille, France, ²Department of Epidemiology, CHU Lille, University of Lille, Lille, France, ³Institute of Immunology, CHU Lille, University of Lille, Lille, France, ⁴Department of Internal Medicine, Roubaix Hospital, Roubaix, France, ⁵Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France
Background/Purpose: Anti-MDA5 dermatomyositis is characterized by little or no muscle involvement, distinct cutaneous features and an increased risk of severe interstitial lung disease (ILD) with…
Abstract Number: 2843 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Victoria Werth¹, David Pearson ², Joyce Okawa ², Rui Feng ³, Josef Concha ², Basil Patel ², Emily Hejazi ², Scott Constantine ⁴, Nancy Dgetluck ⁴ and Barbara White ⁴, ¹Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA and Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ²Philadelphia Veteran Affairs Medical Center, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Norwood, MA
Background/Purpose: Lenabasum is a rationally-designed preferential cannabinoid receptor type 2 agonist that activates resolution of innate immune responses to reduce tissue inflammation and fibrotic processes.…
Abstract Number: 412 • 2019 ACR/ARP Annual Meeting
Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease
Takashi Matsushita¹, Tadahiro Kobayashi ¹, Miyu Kano ¹, Yasuhito Hamaguchi ¹ and Kazuhiko Takehara ², ¹Kanazawa University, Kanazawa, Japan, ²Department of Dermatology, Kanazawa University, Kanazawa, Japan
Background/Purpose: Patients with dermatomyositis (DM) frequently have myositis-specific autoantibodies (MSAs), which are closely associated with different clinical features. Patients with anti-aminoacyl-tRNA synthetase (ARS) antibody (Ab)…
Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Shinichi Nogi ⁴, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁵, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
Abstract Number: 1276 • 2019 ACR/ARP Annual Meeting
Myositis Specific Antibodies and Clinical Features in Patients from Argentina
Amelia Granel¹, Maria de Los Angeles Gargiulo ², Ana Carolina Marcos ³, Ramiro Gomez ⁴, Andrea Braillard Poccard ⁵, Carolina Costi ⁶, Mercedes Garcia ⁷, Malena Viola ⁸, Maria de la Vega ⁹, Belen Barrios ¹⁰, Silvia Papasidero ¹¹, Boris Kisluk ¹², Guillermo Berbotto ¹², Mariana Aciar ¹³, María Crespo Espíndola ¹⁴, Mariano Rivero ¹⁵, Maria N Lojo ¹⁶, Yessica Ponce Delgado ¹⁷, Oscar Rillo ¹⁸, Ramiro Puerta ¹⁹, Isabel Pineda ²⁰, Dafne Capelusnik ²¹, Roberto Movia ²², Darío Scublinsky ²³, Maria Alicia Lazaro ²⁴ and Graciela Gómez ²⁵, ¹Hospital San Roque,Gonnet,La Plata,Buenos Aires.Argentina, La Plata, Buenos Aires, Argentina, ²Instituto de Investigaciones Médicas,Alfredo Lanari.Universidad de Buenos Aires.Argentina, Ciudad de Buenos Aires, Argentina, ³Hospital San Roque,Gonnet,La Plata,Buenos Aires.Argentina, Gonnet, Argentina, ⁴Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital de Clínicas José de San Martin, Buenos Aires, Buenos Aires, Argentina, ⁶Hospital General “San Martín” de la Plata, La Plata, Buenos Aires, Argentina, ⁷Hospital San Martín, La Plata, Argentina, ⁸Centro Reumatologia DOM, Buenos Aires, Buenos Aires, Argentina, ⁹CEIM Investigaciones Medicas, Buenos Aires, Argentina, ¹⁰Hospital Enrique Tornu,Ciudad de Buenos Aires.Argentina, Ciudad de Buenos Aires, Argentina, ¹¹Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ¹²Hospital Escuela Eva Perón.Granadero Baigorria,Santa Fe.Argentina, Granadero Baigorria, Argentina, ¹³Hospital Ntro Señor del Milagro, Salta.Argentina., Salta, Argentina, ¹⁴Hospital Señor del Milagro, Salta, Salta, Argentina, ¹⁵Hospital Británico, Buenos Aires, Buenos Aires, Argentina, ¹⁶Hospital Rossi,La Plata.Argentina, La Plata, Argentina, ¹⁷Hospital Pirovano.Ciudad de Buenos Aires. Argentina, Ciudad de Buenos Aires, Argentina, ¹⁸Hospital Pirovano, Buenos Aires, ¹⁹Hospital Houssay.Vicente Lopez,Buenos Aires.Argentina., Vicente Lopez, Argentina, ²⁰Consultorios Externos Venado Tuerto.Santa Fe.Argentina., Venado Tuerto, Argentina, ²¹Instituto de Rehabilitacion Psicofisica, CABA, Ciudad Autonoma de Buenos Aires, Argentina, ²²Hospital Evita.Lanus.Pcia Buenos Aires. Argentina, Lanus, Argentina, ²³Centros Médicos Ambulatorios SMG, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ²⁴Consultorio Particular, San Isidro, Argentina, ²⁵Instituto de Investigaciones Médicas,Alfredo Lanari.Universidad de Buenos Aires.Argentina., Buenos Aires, Argentina
Background/Purpose: To know the frequency of myositis specific antibodies (MSAs) and myositis associated antibodies( MAAs) and their relation with clinical features in patients with idiopathic…
Abstract Number: 1278 • 2019 ACR/ARP Annual Meeting
Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States
Patompong Ungprasert¹, Wisit Cheungpasitporn ², Charat Thongprayoon ³, Karn Wijarnpreecha ⁴ and Paul Kroner ⁵, ¹Cleveland Clinic, Cleveland, OH, Bangkok, Thailand, ²University of Mississippi Medical Center, Jackson, MS, ³Mayo Clinic Rochester, Rochester, MN, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic Florida, Jacksonville
Background/Purpose: Dermatomyositis (DM) and polymyositis (PM), collectively known as idiopathic inflammatory myositis (IIM), are autoimmune disorders characterized by inflammation of skeletal muscle, especially in the…
Abstract Number: 1279 • 2019 ACR/ARP Annual Meeting
Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management
Alain Sánchez-Rodríguez¹, Citlallyc Josefina Gómez-Ruiz ², Abril Montes-Yanes ² and Gabriel Medrano-Ramírez ², ¹Hospital General de Mexico, Mexico City, Distrito Federal, Mexico, ²Hospital General de Mexico, Rheumatology Department, Ciudad de Mexico, Distrito Federal, Mexico
Background/Purpose: Information regarding response rate and sustained remission in patients with idiopathic inflammatory myopathies (IIM), polymyositis (PM), dermatomyositis (DM), in Hispanics with non-biological treatment is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].